For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin’s Crysvita Crosses Blockbuster Line: 2022 Earnings
February 8, 2023
- Takhzyro Adds Pediatric Indication in US: Takeda
February 8, 2023
- Daiichi Sankyo Espha’s Nexium Generic Hits Japan Market
February 8, 2023
- Japan Ethical Drug Sales Surge 5.8% in December: Crecon
February 8, 2023
- CSL Behring Soon to Launch Home Delivery Service for Hemophilia Therapies
February 8, 2023
- ASKA, Japan Biotech Strike R&D Deal to Create VHH Therapies in OB-GYN Field
February 8, 2023
- Eisai Alzheimer’s Chief Says Lecanemab US Sales “Ahead of Expectations”
February 7, 2023
- Next Astellas CEO Says Weathering Xtandi Cliff Is His Biggest Mission
February 7, 2023
- Teijin Pharma Picks R&D Chief Taneda for President from April
February 7, 2023
- Mochida Abandons Antidepressant MD-120, Lexapro’s Pediatric Use
February 7, 2023
- Astellas’ April-December Sales Up 17% on FX Tailwind; Xtandi Slows in US but Brisk in Japan
February 7, 2023
- Eisai’s 9-Month Profits Sink after One-Time BMS Alliance Gain a Year Ago
February 7, 2023
- Opdivo Extends Streak of Top-Seller Crown to 13 Months: Encise
February 7, 2023
- Astellas EVP Okamura to Become CEO in April
February 6, 2023
- Mitsubishi Chemical Calls It Quit for Medicago, COVID Jab
February 6, 2023
- Takeda Logs Double-Digit Growth, Led by Core Products and Weaker Yen
February 3, 2023
- Nobelpharma’s Nobelzin Granules Now Available, 2 Years after Approval
February 3, 2023
- Takeda Joins Pilot Study of Robotic Drug Delivery Service in Tokyo
February 3, 2023
- Roche/Chugai Drop Gantenerumab Alzheimer’s Program
February 3, 2023
- Chugai’s Sales Hit 1-Trillion-Yen Mark in 2022 on New Launches, Ronapreve
February 3, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…